Health Care & Life Sciences » Biotechnology | Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc. | Ownership

Companies that own Syros Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
4,886,748
14.52%
57,654
0.01%
06/30/2018
ARK Investment Management LLC
1,799,553
5.35%
294,663
0.73%
06/30/2018
Redmile Group LLC
1,631,237
4.84%
-21,003
0.62%
06/30/2018
BlackRock Fund Advisors
1,455,173
4.32%
585,245
0%
06/30/2018
Deerfield Management Company LP
1,268,945
3.77%
0
0.45%
06/30/2018
The Vanguard Group, Inc.
953,538
2.83%
63,146
0%
06/30/2018
Baker Bros. Advisors LP
574,835
1.71%
0
0.05%
06/30/2018
Millennium Management LLC
375,466
1.12%
211,696
0.01%
06/30/2018
SSgA Funds Management, Inc.
351,767
1.05%
150,025
0%
06/30/2018
T. Rowe Price Associates, Inc.
327,479
0.97%
199
0%
06/30/2018

About Syros Pharmaceuticals

View Profile
Address
620 Memorial Drive
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.syros.com
Updated 07/08/2019
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.